Accelerate Diagnostics (NASDAQ: AXDX) and Dextera Surgical (NASDAQ:DXTR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Insider and Institutional Ownership
47.9% of Accelerate Diagnostics shares are owned by institutional investors. Comparatively, 4.5% of Dextera Surgical shares are owned by institutional investors. 50.0% of Accelerate Diagnostics shares are owned by insiders. Comparatively, 10.4% of Dextera Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Accelerate Diagnostics and Dextera Surgical’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Accelerate Diagnostics||$250,000.00||6,260.20||-$66.37 million||($1.20)||-23.54|
|Dextera Surgical||$3.42 million||0.53||-$17.22 million||($1.77)||-0.02|
Dextera Surgical has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than Dextera Surgical, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Accelerate Diagnostics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, Dextera Surgical has a beta of -1.35, meaning that its stock price is 235% less volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Accelerate Diagnostics and Dextera Surgical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Accelerate Diagnostics currently has a consensus price target of $33.00, suggesting a potential upside of 16.81%. Dextera Surgical has a consensus price target of $0.75, suggesting a potential upside of 1,884.13%. Given Dextera Surgical’s stronger consensus rating and higher possible upside, analysts plainly believe Dextera Surgical is more favorable than Accelerate Diagnostics.
This table compares Accelerate Diagnostics and Dextera Surgical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Dextera Surgical beats Accelerate Diagnostics on 8 of the 14 factors compared between the two stocks.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.
Dextera Surgical Company Profile
Dextera Surgical Inc., formerly Cardica, Inc., designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons. Its MicroCutter 5/80 is a commercially available cartridge-based microcutter device with approximately five millimeter shaft diameter, over 80 degrees of articulation, and an approximately 30 millimeter staple line cleared for specified indications for use in the United States, and in the European Union (EU) for a range of indications for use. It designs, manufactures and markets automated anastomotic systems used by surgeons to perform anastomoses during on- or off-pump coronary artery bypass graft procedures and these products include the C-Port xA system, the C-Port Flex A system and the PAS-Port Proximal Anastomosis System.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.